The Management To Optimise Diabetes And MEtabolic Syndrome Risk Reduction Via Nurse-led Intervention (MODERN) Study
Funder
National Health and Medical Research Council
Funding Amount
$1,445,861.00
Summary
There is increasing recognition of society’s responsibility to provide effective and sustainable health care to the entire population and not just selected parts. This practical study will test the impact of a nurse-led, multidisciplinary prevention program to reduce the risk of future cardiovascular events in middle-aged individuals at a high risk of developing cardiovascular disease (CVD) living in regional Australia.
ASPREE is the largest clinical trial ever conducted in Australia and will determine whether daily low dose aspirin prevents disease in healthy older people. The study was well-funded initially but will require additional support to complete the vital final stage of data collection and analysis. This will enable the study to answer important questions about the benefits and risks of aspirin in this age group and its effect on disability free survival.
Assessing The Benefit Of Low Dose Aspirin In The Prevention Of Severe Sepsis.
Funder
National Health and Medical Research Council
Funding Amount
$391,880.00
Summary
Recent discoveries suggest that low doses of aspirin may save lives in patients with infection by limiting its severity. We will conduct a large-scale primary prevention study using daily low-dose aspirin to explore whether this widely used drug can safely prevent severe infection. This study is made possible by collaborative involvement in an existing Australian and USA funded study called ASPREE. Finding a treatment that helps prevent severe effects and outcomes of infection would be a major h ....Recent discoveries suggest that low doses of aspirin may save lives in patients with infection by limiting its severity. We will conduct a large-scale primary prevention study using daily low-dose aspirin to explore whether this widely used drug can safely prevent severe infection. This study is made possible by collaborative involvement in an existing Australian and USA funded study called ASPREE. Finding a treatment that helps prevent severe effects and outcomes of infection would be a major health advance.Read moreRead less
A Randomised Controlled Trial To Prevent Eczema, Food Allergy And Sensitisation Using A Skin Barrier Improvement Strategy
Funder
National Health and Medical Research Council
Funding Amount
$878,163.00
Summary
In this world first study, we will test if building the infant skin barrier by using daily regular skin care treatment can reduce the incidence of eczema. If successful, this trial will alter infant skin care practices and reduce the burden of allergic diseases in our community. Furthermore, as infants with eczema having a poor skin barrier, which possibly increases their risk of developing sensitisation, we will test if this intervention reduces the risk of food allergy.
About 14,000 cases of bowel cancer occur annually in Australia despite the availability of life-saving screening. Most people do not receive recommended screening colonoscopy. We will look at why people at high-risk avoid screening and why people at average risk seek unnecessary screening. We will analyse family history and contacts with the healthcare system that impact screening decisions. We will determine the impact of screening on reducing the number of new cases and deaths.
The D-Health Trial: A Large-scale Population-based Trial Of Vitamin D Supplementation For Improving The Health Of Older Adults
Funder
National Health and Medical Research Council
Funding Amount
$2,591,860.00
Summary
The D-Health Trial is a randomised placebo-controlled trial of vitamin D supplementation for improving the health of older Australian adults. Over 21,000 people were recruited and randomised to monthly doses of vitamin D or placebo. This grant will enable completion of the planned 5 years of supplementation and long-term follow-up of mortality and cancer. The results of the trial will inform decisions about food fortification and/or supplementation with vitamin D.
Low Dose Aspirin And Age-related Macular Degeneration: Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,043,189.00
Summary
Age-related macular degeneration (AMD) is a major cause of visual impairment in advanced countries, responsible for nearly half of all legal blindness in Australia. Due to increased life expectancy, the number of people with this progressive late onset disease will double by 2025. Aspirin could prevent or delay the onset of AMD in older persons but its bleeding risk also needs to be considered. This project will determine whether treatment with low dose aspirin reduces incidence or progression o ....Age-related macular degeneration (AMD) is a major cause of visual impairment in advanced countries, responsible for nearly half of all legal blindness in Australia. Due to increased life expectancy, the number of people with this progressive late onset disease will double by 2025. Aspirin could prevent or delay the onset of AMD in older persons but its bleeding risk also needs to be considered. This project will determine whether treatment with low dose aspirin reduces incidence or progression of AMD.Read moreRead less
Uptake, Sustainability And Impact Of Scaling Up Point-of-care Testing For Sexually Transmissible Infections In Remote And Regional Aboriginal Communities
Funder
National Health and Medical Research Council
Funding Amount
$1,461,788.00
Summary
Aboriginal youth experience unacceptably high rates of curable sexually transmissible infections (STI). Coverage of testing and treatment is insufficient for disease control but could be enhanced via point-of-care (POC) testing. We have been trialling a highly accurate STI/POC diagnostic in the TTANGO (Test, Treat ANd GO) trial. The TTANGO2 partnership will assess the long-term uptake, sustainability and impact of POC testing in 20 Aboriginal health services in regional/remote WA over 5 years.
TB is a global public health problem, responsible for the deaths of 2 million children and young adults annually. Drug resistant strains of TB are emerging and pose a threat even in countries where TB is well controlled, such as Australia. Research undertaken in this CRE will translate into improved treatments, diagnostics and strategies to prevent transmission. The CRE will build capacity for research on TB in our region and provide a legal framework to support public health policy.